Unknown

Dataset Information

0

Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy.


ABSTRACT: The chemotherapeutic doxorubicin (DOX) detrimentally impacts the heart during cancer treatment. This necessitates development of non-cardiotoxic delivery systems that retain DOX anticancer efficacy. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), endothelial cells (hiPSC-ECs), cardiac fibroblasts (hiPSC-CFs), multi-lineage cardiac spheroids (hiPSC-CSs), patient-specific hiPSCs, and multiple human cancer cell lines to compare the anticancer efficacy and reduced cardiotoxicity of single protein encapsulated DOX (SPEDOX-6), to standard unformulated (UF) DOX. Cell viability assays and immunostaining in human cancer cells, hiPSC-ECs, and hiPSC-CFs revealed robust uptake of SPEDOX-6 and efficacy in killing these proliferative cell types. In contrast, hiPSC-CMs and hiPSC-CSs exhibited substantially lower cytotoxicity during SPEDOX-6 treatment compared with UF DOX. SPEDOX-6-treated hiPSC-CMs and hiPSC-CSs maintained their functionality, as indicated by sarcomere contractility assessment, calcium imaging, multielectrode arrays, and RNA sequencing. This study demonstrates the potential of SPEDOX-6 to alleviate cardiotoxic side effects associated with UF DOX, while maintaining its anticancer potency.

SUBMITTER: Arzt M 

PROVIDER: S-EPMC10656302 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy.

Arzt Madelyn M   Gao Bowen B   Mozneb Maedeh M   Pohlman Stephany S   Cejas Romina B RB   Liu Qizhi Q   Huang Faqing F   Yu Changjun C   Zhang Yi Y   Fan Xuemo X   Jenkins Amelia A   Giuliano Armando E AE   Burridge Paul W PW   Cui Xiaojiang X   Sharma Arun A  

Stem cell reports 20230831 10


The chemotherapeutic doxorubicin (DOX) detrimentally impacts the heart during cancer treatment. This necessitates development of non-cardiotoxic delivery systems that retain DOX anticancer efficacy. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), endothelial cells (hiPSC-ECs), cardiac fibroblasts (hiPSC-CFs), multi-lineage cardiac spheroids (hiPSC-CSs), patient-specific hiPSCs, and multiple human cancer cell lines to compare the anticancer efficacy and reduced car  ...[more]

Similar Datasets

| S-EPMC7033479 | biostudies-literature
| S-EPMC10042918 | biostudies-literature
| S-EPMC6760275 | biostudies-literature
| S-EPMC7941910 | biostudies-literature
| S-EPMC11345695 | biostudies-literature
| S-EPMC4855185 | biostudies-literature
| S-EPMC4994528 | biostudies-literature
| S-EPMC9469666 | biostudies-literature
| S-EPMC10135569 | biostudies-literature
| S-EPMC8608383 | biostudies-literature